Dapagliflozin

Product Name:Dapagliflozin
CAS:461432-26-8
MFC21H25ClO6
MW:408.88
EINECS:639-683-0
MOL File:461432-26-8.mol

  ... 正在查看此商品

  分享
Guaranteed Safe Checkout

Table of Contents

Dapagliflozin Product Information

Chemical Profile

Parameter Specification
INN Dapagliflozin propanediol monohydrate
Molecular Formula C21H25ClO6·C3H8O2·H2O
Molecular Weight 408.9 g/mol (free base)
Appearance White to off-white crystalline powder
Solubility Freely soluble in water >100 mg/mL
Storage 25°C (77°F); excursions permitted 15-30°C

Pharmaceutical Data

Attribute Detail
Dosage Forms Film-coated tablets (5mg, 10mg)
Manufacturer AstraZeneca AB
FDA Approval 2014 (Type 2 Diabetes), 2020 (HFrEF), 2021 (CKD)
Bioavailability 78% (oral administration)
Half-life 12.9 hours (mean plasma elimination)

SGLT2 Inhibitors Comparative Analysis

Parameter Dapagliflozin Empagliflozin Canagliflozin
Dosing Frequency QD QD QD
HbA1c Reduction 0.5-0.8% 0.6-0.8% 0.7-1.0%
Cardiovascular Risk Reduction 20% (HHF) 38% (CV Death) 14% (3P-MACE)
Renal Protection 40% eGFR decline risk↓ 39% ESKD risk↓ 30% albuminuria↓
Common AE (%) GU infections (5-9) GU infections (7-9) GU infections (8-10)

Therapeutic Applications

Primary Indications

  • Type 2 Diabetes Mellitus (adjunct to diet/exercise)
  • Heart Failure with Reduced Ejection Fraction (HFrEF)
  • Chronic Kidney Disease (CKD) with albuminuria

Mechanism of Action

Selective SGLT2 inhibition → Blocks renal glucose reabsorption → Increases urinary glucose excretion (≈60-80g/day)

Clinical Usage Guidelines

Dosing Protocol

Indication Initial Dose Maintenance
T2DM 5mg QD AM 10mg QD after 4 weeks
HFrEF 10mg QD Continue indefinitely
CKD 10mg QD eGFR ≥25 mL/min/1.73m²

Monitoring Parameters

  • Renal function: Baseline eGFR & follow-up
  • Volume status (BP/edema)
  • Genital hygiene monitoring

Clinical Case Studies

Case 1: Diabetes Management

52M, HbA1c 8.9%, BMI 32 → Dapa 10mg added to metformin → HbA1c 7.1% at 24 weeks with 3.6kg weight loss

Case 2: Heart Failure Treatment

68F, LVEF 30%, NYHA III → Dapa 10mg initiated → 38%↓ in HF hospitalization at 6 months

Verified Client Success Stories

Massachusetts General Hospital (USA)

300+ T2DM patients treated → 22% reduction in composite renal outcomes vs standard care

Charité Berlin (Germany)

HFrEF cohort (n=150) → 6.2% absolute risk reduction in cardiovascular mortality at 1 year

Apollo Hospitals (India)

CKD patients (eGFR 25-60) → 58% reduction in UACR from baseline at 52 weeks

Request Product Information

Contact our clinical specialists for:

  • Bulk purchasing options
  • Clinical trial materials
  • Custom formulation requests

Email: info@vivalr.com
Tel: (86) 15866781826

0.00
0 条评论
5
0
4
0
3
0
2
0
1
0
成为第一个评论 “Dapagliflozin”

您的邮箱地址不会被公开。 必填项已用 * 标注

这是必填栏。

这是必填栏。

这是必填栏。

评论

目前还没有评论。

类别 
我的购物车
愿望清单
最近浏览
类别
Wait! before you leave…
Get 30% off for your first order
CODE30OFFCopy to clipboard
Use above code to get 30% off for your first order when checkout
比较产品 (4 产品)